3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
40
Breast Neoplasms
12
Prostatic Neoplasms
11
Fallopian Tube Neoplasms
10
Pancreatic Neoplasms
7
Neoplasms
7
Endometrial Neoplasms
7
Glioblastoma
6
Neoplasm Metastasis
5
Carcinoma, Ovarian Epithelial
5
Triple Negative Breast Neoplasms
4
Lung Neoplasms
4
Glioma
4
Small Cell Lung Carcinoma
3
Mesothelioma
3
Cystadenocarcinoma, Serous
3
Cholangiocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Interventions
Cyclophosphamide
21
Cytarabine
15
blinatumomab
13
fludarabine
12
Azacitidine
10
venetoclax
9
fludarabine phosphate
9
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Rituximab
6
Mercaptopurine
6
Daunorubicin
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Etoposide
4
Busulfan
4
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Idarubicin
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neoplasm, Residual
×
niraparib
×
Clear all
NCT03945721
2025-09-29
UNITY
Massachusetts General Hospital
Phase 1
Active not recruiting
21 enrolled